Lilly’s Foundayo Pill Launches Strong: 1,400 Prescriptions in Week 1
Eli Lilly’s new GLP-1 pill shows strong early demand, big weight loss benefits, and promising heart & diabetes results.
XY Feed↓
/ What's going on?
Filter:
Kura Oncology Stock Surges as Darlifarib + Cabozantinib Shows Strong Results in Tough Kidney Cancer Cases
Kura Oncology’s combo drug shrank kidney tumors in early trial, controlled cancer in most patients, stock jumped.
Goldman Sachs Highlights Corvus Pharmaceuticals as a Promising Oral Player in $24 Billion Atopic Dermatitis Market
Goldman sees Corvus as a buy: its oral eczema drug could rival Dupixent and grow into multiple diseases, boosting the stock potential.
AxoGen Stock Jumps as Cigna Adds Coverage for Avance Nerve Graft in Breast Reconstruction
AxoGen shares rose after Cigna will cover its nerve graft from Apr 2026, helping more patients get nerve repair after surgery.
MeiraGTx Stock Drops After $100M Share Offering and Bota-Vec Buy from Johnson & Johnson
MeiraGTx stock fell after $100M share sale to raise cash. Money will fund gene therapy drugs and future launches.
Achieve Life Sciences Stock Jumps as New CEO and $354 Million Funding Fuel Launch of First New Quit-Smoking Pill in 20 Years
Achieve Life Sciences jumps after CEO change, funding news, and progress on smoking/vaping quit drug cytisinicline.
Trump to Launch Federal Research on Psychedelic Drug Ibogaine for PTSD
Trump plans to boost research on ibogaine for PTSD in veterans, despite safety concerns and its illegal status in the US.
Morgan Stanley Sees Big Potential in Kalaris’ Eye Drug TH103
Kalaris Therapeutics gets a boost as Morgan Stanley backs its longer-lasting eye drug, cutting injections for patients.
Abbott Beats Q1 Profit and Revenue Estimates, But Cuts 2026 Outlook After $23B Exact Sciences Deal
Abbott beat Q1 earnings, boosted by cancer diagnostics deal, but cut 2026 profit outlook due to acquisition costs.
Aligos Lands $445 Million China Deal for New Once-Daily Hepatitis B Pill
Aligos partners with Amoytop to bring a new hepatitis B drug to China, boosting cash and speeding access for millions of patients.
RFK Jr. Boosts Hims & Hers: FDA to Ease Restrictions on Popular Peptides
Hims & Hers Health jumps as FDA may ease rules on peptides, but experts warn they may be unsafe and lack proper testing.
PDS Biotech’s PDS01ADC Delivers Impressive 78% Response Rate in Advanced Colorectal Cancer Trial
PDS Biotech drug PDS01ADC improved tumor shrinkage and survival in colorectal cancer trials, showing strong early results.
Immutep Scores FDA Orphan Drug Win for Rare Cancer Treatment Efti
Immutep’s efti shows strong tumor shrinkage in rare cancer STS, earning FDA orphan status to speed development and approval.
Praxis Precision Medicines Shares Surge After FDA Accepts NDA for Ulixacaltamide in Essential Tremor
Praxis Precision Medicines stock jumps as Food and Drug Administration reviews new tremor drug showing strong results and safety.
Obsidian Therapeutics to Merge with Galera and Raise $350 Million to Advance TIL Cell Therapy
Galera and Obsidian merge to form OBX, advancing TIL cancer therapy for melanoma & lung cancer, backed by $350M funding.
Avanos Medical to Be Acquired by American Industrial Partners for $1.27 Billion
Avanos Medical is being bought by AIP for $1.27B in cash. Shareholders get $25 per share, a big premium. Company goes private in 2026.
Travere Wins Full FDA Approval for FILSPARI – First-Ever Treatment for Rare Kidney Disease FSGS
FDA approved FILSPARI for FSGS kidney disease, showing it lowers protein in urine and slows damage. It offers a new treatment option for patients with few choices.
Novo Nordisk Teams Up with OpenAI: AI Supercharges the Fight Against Obesity
Novo Nordisk teams with OpenAI to use AI for faster drug discovery, production and sales, aiming to catch rivals like Eli Lilly.
Mayo Clinic Partners with Sana Biotech: A Potential One-Shot Treatment for Type 1 Diabetes
Sana + Mayo Clinic are testing SC451, a cell therapy that may treat type 1 diabetes without daily insulin shots or immune drugs.
Eye Doctor and Fox News Regular Eyed as New Head of FDA Vaccine Division
FDA may pick Dr. Hemmati to lead CBER, which could speed up vaccine and biotech drug approvals, but decision is not final.
Analysts Turn Bullish on Biohaven, Caris, and Veracyte
Canaccord says Biohaven is undervalued and could rise on epilepsy trial results. Jefferies likes Caris Life Sciences and Veracyte, citing strong growth in cancer diagnostics and solid finances.
TD Securities Sees Strong 2026 Growth for Tempus AI
TD Cowen upgraded Tempus AI to Buy, $65 target, citing strong growth in AI pharma tools despite recent stock drop.
Jhunjhunwala-Backed IKS in Advanced Talks to Buy Nasdaq’s TruBridge for $600M
IKS nearing $600M buy of TruBridge to boost US healthcare billing/RCM, expand AI-driven services and market share.
Pancreatic Cancer Breakthrough: New Daily Pill Nearly Doubles Survival in Major Trial
New drug daraxonrasib from Revolution Medicines doubled survival in pancreatic cancer (13.2 vs 6.7 months) and cut death risk by 60% in Phase 3.
Allogene’s Off-the-Shelf CAR-T Wipes Out Hidden Cancer Cells in 58% of High-Risk Lymphoma Patients – Early Trial Success
Allogene’s CAR-T cema-cel showed strong early results in lymphoma, removing hidden cancer better than watchful waiting with good safety.
Spyre’s SPY001 Delivers Strong Early Results in Ulcerative Colitis Trial – Shares Jump
Spyre drug SPY001 showed strong IBD results, improving symptoms and remission in trials, boosting shares and future outlook.
IDEAYA Shares Surge After Positive Phase 2/3 Results in Hard-to-Treat Eye Cancer
New drug combo shows strong results in rare eye cancer, slowing disease and shrinking tumors; approval filing planned for 2026.
Analysts Abandon Replimune: Stock Drops Sharply After Second FDA Rejection
Replimune shares plunged after the FDA issued a second rejection for its skin cancer drug RP1, prompting multiple analyst downgrades.
FDA Rejects Replimune’s Skin Cancer Drug for the Second Time
FDA again rejects Replimune’s skin cancer drug RP1, saying studies don’t prove it works; shares halted, setback for company.
FDA Accepts Telix Pixclara NDA: Brain Cancer Imaging Tool on Track for September 2026 Decision
Telix’s Pixclara brain cancer scan got FDA review accepted. It helps detect tumors vs treatment effects. Decision due 2026.
Sun Pharma Makes Massive $12 Billion Binding Offer for US Firm Organon
Sun Pharma fell 4% after a $12B bid for Organon, raising debt worries despite strong cash and ongoing deal talks.
Wall Street Analysts Turn Bullish on 3 Promising Biotech Stocks (Buy Ratings)
Analysts see big upside in UroGen, Rapport, and Milestone, driven by strong drugs, upcoming data, and underestimated market potential.
Invivyd Drops Major Update: COVID Study on Track + New Measles Super-Antibody Discovered
Invivyd just announced major progress on its COVID-19 prevention study and a potential first-in-class measles antibody (VMS063).
Wolfe Research Initiates Coverage on Palisade Bio and Avalo Therapeutics with Strong Buy Calls
Wolfe Research: PALI “Outperform” ($7) eyes 2027 ulcerative colitis trial; AVTX “Outperform” ($48) waits May LOTUS Phase 2 readout.
MacroGenics’ LINNET Trial Back on Track After FDA Removes Partial Hold
FDA lifted hold on MacroGenics’ cancer study. New patients can join again; drug helps immune system fight tough ovarian cancers.
Assertio Agrees to $125 Million All-Cash Buyout by Garda Therapeutics
Assertio is being bought by Garda for $18/share + possible bonus if Sprix hits goals; deal closes June 2026, company goes private.
Wall Street Goes Bullish on Two Biotech Stocks: INBX and MPLT
Stifel & Needham back INBX & MPLT: promising cancer & brain drugs, strong safety, big market potential.
Plus Therapeutics Stock Jumps After FDA Orphan Drug Win for Kids’ Rare Brain Tumors
Plus Therapeutics’ REYOBIQ gets FDA orphan drug status for rare kids’ brain tumors.
ANI Pharmaceuticals Stock Jumps After FDA OKs New Generic Heart Drug
ANI Pharma shares jump as it launches FDA-approved generic Monoket to prevent chest pain from heart disease.
Oscar Health CEO Buys $11.9 Million of Stock
Oscar Health CEO bought $11.9M in shares after stock payout, showing strong confidence. Shares jumped.
Stifel Sees 134% Upside in Summit Therapeutics as Ivonescimab Eyes $200B Market
Stifel rates Summit Therapeutics a Buy. Its new cancer drug looks promising, and strong trial results could send the stock much higher.
Insmed Discontinues Brensocatib HS Program After Phase 2b CEDAR Study Misses All Endpoints
Insmed’s HS drug failed to beat placebo in a mid-stage trial, though it was safe. Development for this condition has been stopped.
Gilead’s $5B Tubulis Deal Validates ADC Space – Bullish for Sutro Biopharma
Leerink sees major tailwind for Sutro Biopharma and initiates coverage with $38 price target.
Perrigo Stock Jumps on Takeover Rumors from German Drugmaker Stada
Perrigo Co. stock rose on takeover rumors, possibly by Stada Arzneimittel AG. No deal confirmed yet.
Gilead’s Third Deal of 2026: $3.15B Buyout of ADC Specialist Tubulis
Gilead buys German biotech Tubulis for $3.15B to boost cancer-fighting “smart” drugs called ADCs. Deal closes Q2 2026.
FDA Gives Fast Track Boost to Climb Bio’s Budoprutug for Primary Membranous Nephropathy
Climb Bio stock jumps after FDA fast-track for budoprutug, a new drug for rare kidney disease pMN.
AC Immune & Lilly Team Up Again to Stop Alzheimer’s with Brain-Targeting Drugs
AC Immune updates Eli Lilly deal to develop pill-based Tau drugs for Alzheimer’s, aiming to stop disease early with promising preclinical results.
Bio-Rad Faces Headwinds as Citi Downgrades Shares to Neutral
Citi downgrades Bio-Rad to Neutral, citing weak chromatography growth and China market risks; price target cut to $300.
Organogenesis’ PuraPly AM Shows Strong Success in Diabetic Foot Ulcer Trial
Organogenesis Holdings says PuraPly AM helps diabetic foot ulcers heal faster than standard care alone in a clinical trial.
Insurer Stocks Soar After CMS Finalizes 2027 Medicare Payments
CMS boosts 2027 Medicare payments 2.5%, giving insurers $13B+, keeping plans stable and seniors’ benefits solid. Stocks jump.
Amgen’s Easy “On-Body” Tepezza Shot Crushes Phase 3 — Viridian Stock Plunges
Viridian shares fell after Amgen’s new, easy Tepezza shot showed strong results for Thyroid Eye Disease.
ImmunityBio Quickly Fixes FDA Ad Concerns: Podcast Pulled, TV Spot Never Aired
ImmunityBio addressed FDA ad concerns, removed a podcast, and clarified ANKTIVA info while tightening rules on future promotions.
Tyra Biosciences Receives Buy Rating – Key 2026 Data Ahead
Tyra Biosciences’ dabogratinib shows promise: works well for bladder cancer & dwarfism with fewer side effects. Big 2026 trials ahead.
Neurocrine Expands Rare Disease Portfolio with $2.9B Soleno Buy
Neurocrine will buy Soleno for $2.9B, adding VYKAT XR, the first drug for extreme hunger in rare Prader-Willi syndrome.
Vericel Secures Up to $197M BARDA Contract for NexoBrid – 10-Year Deal to Bolster U.S. Burn and Blast Injury Preparedness
Vericel won a 10-year, $197M BARDA deal to supply NexoBrid, a burn treatment, and expand its use and production in the U.S.
Wedbush Upgrades Arcus Biosciences Ahead of Key 2026 Clinical Data
Wedbush upgraded Arcus Biosciences with a new $41 price target and added the stock to its Best Ideas List ahead of major 2026 clinical updates for casdatifan in kidney cancer.
FDA Fast Track Boosts Context Therapeutics’ CTIM-76 for Hard-to-Treat Ovarian Cancer
Context Therapeutics’ CTIM-76 wins FDA Fast Track Designation for platinum-resistant ovarian cancer. Phase 1a trial ongoing with interim data expected in June 2026.
Immunovant’s Batoclimab Flops in Phase 3 Thyroid Eye Disease Trials
Immunovant’s batoclimab failed key TED trials, but high doses helped; focus now shifts to next-gen drug IMVT-1402 for autoimmune disease.
Cocrystal Pharma Gets FDA Fast Track for Norovirus Treatment & Prevention
FDA fast-tracks a new oral drug, CDI-988, to treat and prevent norovirus—a common stomach virus affecting millions worldwide.
Lipocine’s Oral PPD Pill Shows Strong Promise in Key Group Despite Missing Main Goal
Lipocine’s oral pill for postpartum depression missed main goal but showed fast, lasting benefits in some patients with good safety profile.
FDA Tightens Rules on Copycat Ozempic and Wegovy – No More Routine Compounding
FDA limits copycat GLP-1 drugs; pharmacies can only make them during shortages. Original meds like Foundayo now safer & more available.
ALTO-101 Misses Primary Endpoint in Schizophrenia Trial, Company Shifts Focus to ALTO-207
ALTO-101 misses Phase 2 endpoints but shows signals. Alto pivots to ALTO-207 in treatment-resistant depression with strong prior data.
Connect Biopharma Insider Buying: Panacea Venture Adds 1.16M Shares
Director James Huang and Panacea Venture bought 1.16 million shares of Connect Biopharma at $3.45, boosting their stake to 21.2%.
FDA Delays Popular Nicotine Pouches Over Youth Risks
Popular nicotine pouches like Zyn and Velo remain unapproved in the US despite FDA fast-track. Agency hesitates due to rising youth use and addiction concerns.
FDA Just Approved Foundayo: The Only GLP-1 Weight-Loss Pill You Can Take Anytime, Anywhere
Eli Lilly’s Foundayo (orforglipron) is now FDA-approved — the only GLP-1 pill for weight loss you can take any time of day, with or without food or water. Average 27 lb loss.
Cyclerion Stock Soars on $380M Merger with Korsana to Fight Alzheimer’s
Cyclerion stock surges after announcing a merger with Korsana Biosciences and $380M in new funding to advance a next-gen Alzheimer’s antibody.
ORIC Shares Slide on Higher-Dose Side Effects — But 400mg Rinzimetostat Looks Best-in-Class
ORIC shares plunged after Phase 1b data showed higher side effects at 600mg rinzimetostat.
ImmunityBio Scores $100 Million Cash Boost – $75M Non-Dilutive – to Supercharge Global Expansion
ImmunityBio strengthens its balance sheet with $100 million financing, including $75M non-dilutive funding from Oberland Capital and $25M debt conversion.
FDA Moving to Bring Back Popular Injectable Peptides
The FDA is moving to allow compounding pharmacies to produce over a dozen banned injectable peptides. RFK Jr. says he's a big fan and has used them with great results.
Agios Moves Closer to Fast FDA Approval for New Sickle Cell Pill
Agios is pursuing accelerated FDA approval for mitapivat, a new oral pill for sickle cell disease. The RISE UP trial showed better hemoglobin levels, fewer pain crises, and good safety.
Oppenheimer Sees $1 Billion Potential in Passage Bio’s PBFT02 for FTD
Oppenheimer just started coverage on Passage Bio with an Outperform rating and $30 price target. They call the recent pullback a buying opportunity ahead of key PBFT02 data in H1 2026.
Caribou Biosciences Jumps as FDA Grants RMAT Designation to Off-the-Shelf CAR-T Therapy CB-011 for Multiple Myeloma
Caribou Biosciences stock surges after FDA grants RMAT designation to CB-011, its off-the-shelf allogeneic CAR-T for multiple myeloma. Phase 1 data: 92% ORR, 75% complete response in BCMA-naïve patients. More data expected 2026.
Scholar Rock Shares Jump as Apitegromab BLA Resubmitted to FDA for SMA Treatment
Scholar Rock resubmits its BLA for apitegromab to treat SMA. FDA acceptance expected in 30 days, PDUFA target late September 2026.
Biogen Buys Apellis for $5.6 Billion: Two New Drugs Supercharge Growth in Rare Diseases & Kidney Care
Biogen is acquiring Apellis for $5.6 billion, adding two approved drugs (Syfovre & Empaveli) for eye disease and rare kidney conditions. Boosts growth and nephrology pipeline.
Lilly Buys Centessa for $7.8 Billion to Fight Sleep Disorders
Eli Lilly is acquiring Centessa in a $7.8 billion deal to develop breakthrough OX2R drugs for narcolepsy, idiopathic hypersomnia, and excessive daytime sleepiness.
PepGen’s Low-Dose DM1 Data Falls Flat: Minimal Splicing Correction and No Clear Functional Benefit
PepGen’s latest low-dose (5 mg/kg) DM1 data shows minimal splicing correction and almost no functional improvement over placebo.
Alumis Stock Crashes in Classic “Sell the News” After Strong Phase 3 Psoriasis Data
Alumis shares plunged after strong Phase 3 psoriasis data for envudeucitinib. HC Wainwright cuts price target to $25 citing rising competition.
Lilly Signs $2.75B AI Drug Deal with Hong Kong’s Insilico Medicine
Eli Lilly has signed a $2.75 billion deal with Hong Kong-listed AI biotech Insilico Medicine for a GLP-1 diabetes drug.
Wells Fargo Calls Boston Scientific’s WATCHMAN Trial “Good, Not Great”
Wells Fargo says Boston Scientific’s CHAMPION-AF trial met all endpoints for WATCHMAN FLX but calls results “good, not great” due to slightly higher stroke rate vs blood thinners.
Morgan Stanley Boosts Insmed on Strong Brinsupri Outlook
Morgan Stanley upgrades Insmed to Overweight and raises price target to $212.
Big Move in Autoimmune Space: Aurinia to Buy Kezar Life Sciences
Aurinia Pharmaceuticals has agreed to acquire Kezar Life Sciences for $6.955 in cash per share plus a Contingent Value Right (CVR).
Game-Changer for IPF: Inhaled Tyvaso Preserves Lung Function in Major TETON-1 Study
The United Therapeutics TETON-1 trial shows that inhaled Tyvaso preserves lung function by 130 mL versus placebo and reduces disease progression. Positive results were seen across all patient groups, with an FDA filing planned for this summer.
Viridian’s Elegrobart Data: Promising Proptosis Win, But Missing the Full Picture for Thyroid Eye Disease
Viridian highlights 54% proptosis response for Elegrobart in TED, but secondary endpoints like inflammation and diplopia showed limited gains.
FDA Fast-Tracks Zymeworks’ New Ovarian Cancer Drug ZW191
Zymeworks receives U.S. FDA Fast Track Designation for ZW191, its FRα-targeting antibody-drug conjugate for advanced platinum-resistant ovarian cancer.
“Sell the News” Hits Rocket: Kresladi Approved, But Shares Fall
Rocket Pharmaceuticals won FDA approval for Kresladi and a valuable Priority Review Voucher, yet the stock dropped. Analysts explain the "sell the news" reaction, dilution concerns, and why they remain bullish with Outperform ratings.
Needham Initiates Buy Rating on BioAge Labs with $50 Price Target
Analysts are bullish on lead asset BGE-102, an oral NLRP3 inhibitor for cardiovascular risk in obese patients.
AstraZeneca Shares Jump as COPD Drug Tozorakimab Delivers Positive Results
AstraZeneca’s experimental drug tozorakimab significantly reduced COPD flare-ups in two Phase 3 trials. Promising new hope for millions of patients with chronic lung disease.
FDA Approves KRESLADI: First Gene Therapy for Rare, Life-Threatening Childhood Immune Disorder
The FDA has approved KRESLADI, Rocket Pharma’s one-time gene therapy for children with severe LAD-I — a rare, life-threatening immune disorder.
H.C. Wainwright Initiates Buy Rating on Palisade Bio with $7 Target
Analysts say PALI-2108 offers better safety and efficacy for ulcerative colitis compared to older PDE4 inhibitors.
Kodiak Sciences Stock Surges After Strong Phase 3 Eye Drug Results
Kodiak Sciences shares surged after Zenkuda hit its primary endpoint in the GLOW2 Phase 3 study for diabetic retinopathy.
WVE-007 Shows Muscle-Preserving Fat Loss in Early Data, But Weight Reduction Remains Modest
Wave Life Sciences' WVE-007 (INHBE-targeted) showed ~5% total fat reduction and 14% visceral fat drop with muscle preserved after one dose. Early results are modest (1% weight loss), but support infrequent dosing as potential GLP-1 complement.
Emergent BioSolutions Secures $60M+ in New Smallpox Defense Contracts
Emergent BioSolutions wins $54M U.S. government contract for VIGIV plus $6.6M international orders for ACAM2000 smallpox vaccine.
Why Merck’s Big CML Bet Makes Enliven’s ELVN-001 a Takeover Star
Merck’s $6.7B acquisition of Terns Pharmaceuticals highlights huge potential in CML therapies. Why analysts see Enliven’s ELVN-001 as a best-in-class winner with strong takeover appeal.
FDA Approves First Brain-Penetrating Treatment for Hunter Syndrome in Nearly 20 Years
The FDA has approved Denali’s AVLAYAH, the first brain-penetrating enzyme therapy for Hunter syndrome (MPS II) in nearly 20 years.
FDA Greenlights Relacorilant + Nab-Paclitaxel for Hard-to-Treat Ovarian Cancer
The FDA has approved Corcept's relacorilant (Lifyorli) in combination with nab-paclitaxel for platinum-resistant ovarian, fallopian tube, or peritoneal cancer, showing improved survival by several months.
BofA Calls Bicara Therapeutics a Buy – Sees Ficerafusp Alfa as Transformative
BofA starts coverage on Bicara Therapeutics with a Buy rating and $35 price target. Ficerafusp alfa shows strong potential in head and neck cancer with clear differentiation over standard care.
Sarepta Hits Early Win With New siRNA Drugs for Rare Muscle Diseases – Beating Rivals on Delivery and Safety
Sarepta just shared first test results for two new medicines aimed at rare muscle diseases FSHD1 and DM1. Early data show the drugs reach high levels in muscle safely, with no serious side effects. Shares jumped.
Why Investors Punished Maze Stock Despite Strong MZE829 Diabetes Data
Maze’s new kidney pill MZE829 cut harmful protein in urine by 35.6% in its Phase 2 trial — including patients with diabetes. Stock still fell 30% as analysts say “don’t compare it to Vertex” but remain very bullish.
Anavex Pulls Alzheimer’s Drug Application in Europe After EMA Feedback
Anavex Life Sciences has withdrawn its EU marketing application for blarcamesine as an add-on therapy for early Alzheimer’s. Shares fell sharply after EMA committee feedback.
Morgan Stanley Bullish on Immix Biopharma: Sees $1B+ Opportunity for NXC-201 CAR-T Therapy
Morgan Stanley initiated coverage on Immix Biopharma with an Overweight rating and $20 price target.